Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

Shahina Daar, Anil Pathare, Hanspeter Nick, Ulrike Kriemler-Krahn, Abdel Hmissi, Dany Habr, Ali Taher

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

This subgroup analysis evaluated the effect of once-daily oral deferasirox on labile plasma iron (LPI) levels in patients from the prospective, 1-yr, multicentre ESCALATOR study. Mean baseline liver iron concentration and median serum ferritin levels were 28.6 ± 10.3 mg Fe/g dry weight and 6334 ng/mL respectively, indicating high iron burden despite prior chelation therapy. Baseline LPI levels (0.98 ± 0.82 μmol/L) decreased significantly to 0.12 ± 0.16 μmol/L, 2 h after first deferasirox dose (P = 0.0006). Reductions from pre- to post-deferasirox administration were also observed at all other time points. Compared to baseline, there was a significant reduction in preadministration LPI that reached the normal range at week 4 and throughout the remainder of the study (P ≤ 0.02). Pharmacokinetic analysis demonstrated an inverse relationship between preadministration LPI levels and trough deferasirox plasma concentrations. Once-daily dosing with deferasirox ≥20 mg/kg/d provided sustained reduction in LPI levels in these heavily iron-overloaded patients, suggesting 24-h protection from LPI. Deferasirox may therefore reduce unregulated tissue iron loading and prevent further end-organ damage.

Original languageEnglish
Pages (from-to)454-457
Number of pages4
JournalEuropean Journal of Haematology
Volume82
Issue number6
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Thalassemia
Chelating Agents
Iron
Therapeutics
deferasirox
Chelation Therapy
Ferritins
Multicenter Studies
Reference Values
Pharmacokinetics
Weights and Measures

Keywords

  • β-thalassaemia
  • Deferasirox
  • Labile plasma iron
  • Oral
  • Pharmacokinetic

ASJC Scopus subject areas

  • Hematology

Cite this

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. / Daar, Shahina; Pathare, Anil; Nick, Hanspeter; Kriemler-Krahn, Ulrike; Hmissi, Abdel; Habr, Dany; Taher, Ali.

In: European Journal of Haematology, Vol. 82, No. 6, 06.2009, p. 454-457.

Research output: Contribution to journalArticle

Daar, Shahina ; Pathare, Anil ; Nick, Hanspeter ; Kriemler-Krahn, Ulrike ; Hmissi, Abdel ; Habr, Dany ; Taher, Ali. / Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. In: European Journal of Haematology. 2009 ; Vol. 82, No. 6. pp. 454-457.
@article{10ed7d466615421fac27075790147161,
title = "Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia",
abstract = "This subgroup analysis evaluated the effect of once-daily oral deferasirox on labile plasma iron (LPI) levels in patients from the prospective, 1-yr, multicentre ESCALATOR study. Mean baseline liver iron concentration and median serum ferritin levels were 28.6 ± 10.3 mg Fe/g dry weight and 6334 ng/mL respectively, indicating high iron burden despite prior chelation therapy. Baseline LPI levels (0.98 ± 0.82 μmol/L) decreased significantly to 0.12 ± 0.16 μmol/L, 2 h after first deferasirox dose (P = 0.0006). Reductions from pre- to post-deferasirox administration were also observed at all other time points. Compared to baseline, there was a significant reduction in preadministration LPI that reached the normal range at week 4 and throughout the remainder of the study (P ≤ 0.02). Pharmacokinetic analysis demonstrated an inverse relationship between preadministration LPI levels and trough deferasirox plasma concentrations. Once-daily dosing with deferasirox ≥20 mg/kg/d provided sustained reduction in LPI levels in these heavily iron-overloaded patients, suggesting 24-h protection from LPI. Deferasirox may therefore reduce unregulated tissue iron loading and prevent further end-organ damage.",
keywords = "β-thalassaemia, Deferasirox, Labile plasma iron, Oral, Pharmacokinetic",
author = "Shahina Daar and Anil Pathare and Hanspeter Nick and Ulrike Kriemler-Krahn and Abdel Hmissi and Dany Habr and Ali Taher",
year = "2009",
month = "6",
doi = "10.1111/j.1600-0609.2008.01204.x",
language = "English",
volume = "82",
pages = "454--457",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

AU - Daar, Shahina

AU - Pathare, Anil

AU - Nick, Hanspeter

AU - Kriemler-Krahn, Ulrike

AU - Hmissi, Abdel

AU - Habr, Dany

AU - Taher, Ali

PY - 2009/6

Y1 - 2009/6

N2 - This subgroup analysis evaluated the effect of once-daily oral deferasirox on labile plasma iron (LPI) levels in patients from the prospective, 1-yr, multicentre ESCALATOR study. Mean baseline liver iron concentration and median serum ferritin levels were 28.6 ± 10.3 mg Fe/g dry weight and 6334 ng/mL respectively, indicating high iron burden despite prior chelation therapy. Baseline LPI levels (0.98 ± 0.82 μmol/L) decreased significantly to 0.12 ± 0.16 μmol/L, 2 h after first deferasirox dose (P = 0.0006). Reductions from pre- to post-deferasirox administration were also observed at all other time points. Compared to baseline, there was a significant reduction in preadministration LPI that reached the normal range at week 4 and throughout the remainder of the study (P ≤ 0.02). Pharmacokinetic analysis demonstrated an inverse relationship between preadministration LPI levels and trough deferasirox plasma concentrations. Once-daily dosing with deferasirox ≥20 mg/kg/d provided sustained reduction in LPI levels in these heavily iron-overloaded patients, suggesting 24-h protection from LPI. Deferasirox may therefore reduce unregulated tissue iron loading and prevent further end-organ damage.

AB - This subgroup analysis evaluated the effect of once-daily oral deferasirox on labile plasma iron (LPI) levels in patients from the prospective, 1-yr, multicentre ESCALATOR study. Mean baseline liver iron concentration and median serum ferritin levels were 28.6 ± 10.3 mg Fe/g dry weight and 6334 ng/mL respectively, indicating high iron burden despite prior chelation therapy. Baseline LPI levels (0.98 ± 0.82 μmol/L) decreased significantly to 0.12 ± 0.16 μmol/L, 2 h after first deferasirox dose (P = 0.0006). Reductions from pre- to post-deferasirox administration were also observed at all other time points. Compared to baseline, there was a significant reduction in preadministration LPI that reached the normal range at week 4 and throughout the remainder of the study (P ≤ 0.02). Pharmacokinetic analysis demonstrated an inverse relationship between preadministration LPI levels and trough deferasirox plasma concentrations. Once-daily dosing with deferasirox ≥20 mg/kg/d provided sustained reduction in LPI levels in these heavily iron-overloaded patients, suggesting 24-h protection from LPI. Deferasirox may therefore reduce unregulated tissue iron loading and prevent further end-organ damage.

KW - β-thalassaemia

KW - Deferasirox

KW - Labile plasma iron

KW - Oral

KW - Pharmacokinetic

UR - http://www.scopus.com/inward/record.url?scp=65349110837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349110837&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2008.01204.x

DO - 10.1111/j.1600-0609.2008.01204.x

M3 - Article

VL - 82

SP - 454

EP - 457

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 6

ER -